Pharmaceutical Development
Health Sciences
Medical Affairs

The Team

The Kompas Medical Service Inc. team is composed of a lead consultant working with a network of international experts, providing integrated services with the highest professional standards.

Dan Chiche MD, MBA, has a successful 20 year career history in the top tier pharmaceutical companies (Glaxo and Bristol-Myers Squibb) as an executive in Clinical Research and Medical Affairs. He is a Medical Doctor with additional training in biostatistics (Master) and business administration. He has been involved in key clinical development of compounds in various therapeutic areas, including infectious diseases, HIV, hepatitis, influenza, rheumatoid arthritis, hypertension, diabetes, COPD, asthma, pain oncology and is fully familiarized with clinical research standards: ICH, FDA and EMEA. During his 20 years with major pharmaceuticals, he has worked with business colleagues in order to maximize product properties, using medical communication tools, developing medical concepts and effective KOL networks. As an executive manager, he has been directly involved in the optimization of human resources and processes to deliver, on schedule, high quality outputs in clinical research and medical affairs. In 2007, Dan founded Kompas Medical Services Inc., a company providing services to Biotechs, Pharmas, and other institutions. Dan was a member of board of directors of 3 biotechnology companies based in Montreal, Quebec, Canada.

Dan is NEOMED’s Chief Medical Officer. NEOMED is a novel type of not for profit organization which will pioneer an approach to bridge the gap between early innovations and the health care needs of society.In this role, Dan aims to demonstrate the value of this new R&D model by bringing assets to the clinical proof-of-concept stage of maturation. Dan also serves a key role in the review of potential project candidates where he brings the long-term medical vision and a deep understanding of R&D opportunities and constraints to NEOMED’s search for value creation.